Steinberg Global Asset Management’s NovoCure NVCR Stock Holding History

Steinberg Global Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$6.59M	Buy	136,765 +1,371	+1%	+$66K	1.03%	25
2018 Q4	$4.53M	Sell	135,394 -1,873	-1%	-$68.5K	0.78%	38
2018 Q3	$7.19M	Buy	137,267 +11,073	+9%	+$441K	1.02%	28
2018 Q2	$3.95M	Buy	126,194 +19,143	+18%	+$532K	0.58%	58
2018 Q1	$2.33M	Buy	+107,051	New	+$2.3M	0.34%	81

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Steinberg Global Asset Management's NVCR Position: Q1 2019 in Review

Steinberg Global Asset Management increased its NovoCure (NVCR) stake by 1% in Q1 2019, buying an estimated $66K and bringing the position to 136,765 shares worth $6.59M. The position accounts for 1.03% of the portfolio, ranked #25.

Steinberg Global Asset Management first reported a position in NVCR in Q1 2018 and has held it in 5 quarters since. The position peaked at $7.19M in Q3 2018. 200 funds tracked by Wall St. Rank hold NVCR as of Q1 2019.

Steinberg Global Asset Management held 136,765 shares of NovoCure worth $6.59M as of Q1 2019.
Steinberg Global Asset Management bought 1,371 NovoCure shares in Q1 2019, an estimated $66K.
NovoCure made up 1.03% of Steinberg Global Asset Management's portfolio in Q1 2019, its #25 holding.
Steinberg Global Asset Management first reported a position in NovoCure in Q1 2018 and has held it in 5 quarters since.
Steinberg Global Asset Management's NovoCure position peaked at $7.19M in Q3 2018.
200 funds tracked by Wall St. Rank held NovoCure as of Q1 2019.

Based on Steinberg Global Asset Management's 13F filing for Q1 2019, filed 15 Apr 2019.